Glomerular disease: Difference between revisions
Line 217: | Line 217: | ||
! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Causes and associations | ! rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Causes and associations | ||
! colspan="7" rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |History and Symtoms | ! colspan="7" rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |History and Symtoms | ||
! colspan=" | ! colspan="7" align="center" style="background:#4479BA; color: #FFFFFF;" + |Laboratory Findings | ||
! colspan="3" |Pathology | |||
! rowspan="3" |Comments | |||
|- | |- | ||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Hyperlipidemia and hypercholesterolemia | ! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Hyperlipidemia and hypercholesterolemia | ||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Nephrotic features | ! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Nephrotic features | ||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Nephritic features | ! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Nephritic features | ||
! rowspan="2" |Antibodies | |||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |ANCA | ! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |ANCA | ||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Anti-glomerular basement membrane antibody (Anti-GBM antibody) | ! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Anti-glomerular basement membrane antibody (Anti-GBM antibody) | ||
Line 239: | Line 242: | ||
| rowspan="10" align="center" style="background:#4479BA; color: #FFFFFF;" + |Acute Nephritic Syndromes | | rowspan="10" align="center" style="background:#4479BA; color: #FFFFFF;" + |Acute Nephritic Syndromes | ||
! colspan="2" |[[Poststreptococcal glomerulonephritis|Poststreptococcal Glomerulonephritis]] | ! colspan="2" |[[Poststreptococcal glomerulonephritis|Poststreptococcal Glomerulonephritis]] | ||
|Post infectios: group A beta-hemolytic streptococcus | |||
|History of prior skin or throat step infection | |||
|<nowiki>+/-</nowiki> | |||
|<nowiki>+/-</nowiki> | |||
|<nowiki>+/-</nowiki> | |||
|<nowiki>+/-</nowiki> | |||
|<nowiki>+/-</nowiki> | |||
|<nowiki>+/-</nowiki> | |||
|<nowiki>+/-</nowiki> | |||
|<nowiki>+/-</nowiki> | |||
|<nowiki>+/-</nowiki> | |||
| | | | ||
* Anti-DNA antibodies | |||
* Anti-C1q antibodies | |||
* Antineutrophil cytoplasmic antibodies (ANCA) | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
* diffuse proliferative glomerulonephritis | |||
* prominent endocapillary proliferation and numerous neutrophils | |||
* small subepithelial hump-shaped deposits | |||
| | | | ||
| | | | ||
| | |Pathologic involvement correlates with the clinical findings | ||
|- | |- | ||
! colspan="2" |[[Subacute bacterial endocarditis|Subacute Bacterial Endocarditis]] | ! colspan="2" |[[Subacute bacterial endocarditis|Subacute Bacterial Endocarditis]] | ||
|Systemic immune reaction to bacterial endocarditis | |||
|History of infective endocarditis | |||
|<nowiki>+/-</nowiki> | |||
|<nowiki>+/-</nowiki> | |||
|<nowiki>+/-</nowiki> | |||
|<nowiki>+/-</nowiki> | |||
|<nowiki>+/-</nowiki> | |||
|<nowiki>+/-</nowiki> | |||
|<nowiki>+/-</nowiki> | |||
|<nowiki>+/-</nowiki> | |||
|<nowiki>+/-</nowiki> | |||
| | | | ||
| | | | ||
Line 266: | Line 288: | ||
| | | | ||
| | | | ||
|- | |||
! colspan="2" |[[Lupus nephritis|Lupus Nephritis]] | |||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
Line 308: | Line 323: | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| | |||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
Line 315: | Line 331: | ||
* Diffuse thickening of the [[glomerular basement membrane]] with absence of sub-[[Epithelial cells|epithelial]] and sub-[[endothelial]] deposits | * Diffuse thickening of the [[glomerular basement membrane]] with absence of sub-[[Epithelial cells|epithelial]] and sub-[[endothelial]] deposits | ||
|<nowiki>+ (Linear)</nowiki> | |<nowiki>+ (Linear)</nowiki> | ||
| | |||
| | | | ||
|- | |- | ||
Line 334: | Line 351: | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
| | |||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
Line 342: | Line 360: | ||
* [[Mesangial cell|Mesangial]] proliferation | * [[Mesangial cell|Mesangial]] proliferation | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| | |||
|- | |- | ||
! rowspan="3" |[[Vasculitis|ANCA Small-Vessel Vasculitis]] | ! rowspan="3" |[[Vasculitis|ANCA Small-Vessel Vasculitis]] | ||
! colspan="1" |[[Granulomatosis with polyangiitis|Granulomatosis with Polyangiitis (Wegener's)]] | ! colspan="1" |[[Granulomatosis with polyangiitis|Granulomatosis with Polyangiitis (Wegener's)]] | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 364: | Line 385: | ||
|- | |- | ||
! colspan="1" |[[Microscopic polyangiitis|Microscopic Polyangiitis]] | ! colspan="1" |[[Microscopic polyangiitis|Microscopic Polyangiitis]] | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 383: | Line 406: | ||
|- | |- | ||
! colspan="1" |[[Eosinophilic granulomatosis with polyangiitis|Churg-Strauss Syndrome]] | ! colspan="1" |[[Eosinophilic granulomatosis with polyangiitis|Churg-Strauss Syndrome]] | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 420: | Line 445: | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| | |||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
Line 428: | Line 454: | ||
* [[Mesangial cell|Mesangial]] proliferation and [[Leukocytes|leukocyte]] infiltration | * [[Mesangial cell|Mesangial]] proliferation and [[Leukocytes|leukocyte]] infiltration | ||
|<nowiki>+ (Granular)</nowiki> | |<nowiki>+ (Granular)</nowiki> | ||
| | |||
|- | |- | ||
! colspan="2" |Mesangioproliferative Glomerulonephritis | ! colspan="2" |Mesangioproliferative Glomerulonephritis | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 468: | Line 497: | ||
| + | | + | ||
| - | | - | ||
| | |||
| - | | - | ||
| - | | - | ||
Line 476: | Line 506: | ||
* Fusion of [[podocytes]] | * Fusion of [[podocytes]] | ||
| - | | - | ||
| | |||
|- | |- | ||
! colspan="2" |[[Focal segmental glomerulosclerosis|Focal Segmental Glomerulosclerosis]] | ! colspan="2" |[[Focal segmental glomerulosclerosis|Focal Segmental Glomerulosclerosis]] | ||
Line 497: | Line 528: | ||
| + | | + | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| | |||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
Line 505: | Line 537: | ||
* Effacement of [[podocytes]] | * Effacement of [[podocytes]] | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| | |||
|- | |- | ||
! colspan="2" |[[Membranous glomerulonephritis|Membranous Glomerulonephritis]] | ! colspan="2" |[[Membranous glomerulonephritis|Membranous Glomerulonephritis]] | ||
Line 523: | Line 556: | ||
| + | | + | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| | |||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
Line 531: | Line 565: | ||
* Sub-[[Epithelial cells|epithelial]] [[immune complex]] depositis with 'spike and dome' appearance | * Sub-[[Epithelial cells|epithelial]] [[immune complex]] depositis with 'spike and dome' appearance | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| | |||
|- | |- | ||
! colspan="2" |[[Diabetic nephropathy|Diabetic Nephropathy]] | ! colspan="2" |[[Diabetic nephropathy|Diabetic Nephropathy]] | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 553: | Line 590: | ||
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + | Glomerular Deposition Diseases | ! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + | Glomerular Deposition Diseases | ||
! colspan="2" |[[Light chain nephropathy|Light Chain Deposition Disease]] | ! colspan="2" |[[Light chain nephropathy|Light Chain Deposition Disease]] | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 572: | Line 611: | ||
|- | |- | ||
! colspan="2" |[[Amyloidosis|Renal Amyloidosis]] | ! colspan="2" |[[Amyloidosis|Renal Amyloidosis]] | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 591: | Line 632: | ||
|- | |- | ||
! colspan="2" |Fibrillary-Immunotactoid Glomerulopathy | ! colspan="2" |Fibrillary-Immunotactoid Glomerulopathy | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 610: | Line 653: | ||
|- | |- | ||
! colspan="2" |[[Fabry's disease|Fabry's Disease]] | ! colspan="2" |[[Fabry's disease|Fabry's Disease]] | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 630: | Line 675: | ||
! rowspan="5" align="center" style="background:#4479BA; color: #FFFFFF;" + |Pulmonary-Renal Syndromes: | ! rowspan="5" align="center" style="background:#4479BA; color: #FFFFFF;" + |Pulmonary-Renal Syndromes: | ||
! colspan="2" |[[Goodpasture syndrome|Goodpasture's syndrome]] | ! colspan="2" |[[Goodpasture syndrome|Goodpasture's syndrome]] | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 662: | Line 709: | ||
| | | | ||
+ ([[P-ANCA]]) | + ([[P-ANCA]]) | ||
| | |||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
Line 668: | Line 716: | ||
|<nowiki>- (pauci-immune)</nowiki> | |<nowiki>- (pauci-immune)</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| | |||
| | | | ||
|- | |- | ||
Line 686: | Line 735: | ||
| | | | ||
+ ([[C-ANCA]]) | + ([[C-ANCA]]) | ||
| | |||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
Line 692: | Line 742: | ||
|<nowiki>- (pauci-immune)</nowiki> | |<nowiki>- (pauci-immune)</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| | |||
| | | | ||
|- | |- | ||
! colspan="2" |[[Henoch-Schönlein purpura]] | ! colspan="2" |[[Henoch-Schönlein purpura]] | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 714: | Line 767: | ||
|- | |- | ||
! colspan="2" |[[Cryoglobulinemia]] | ! colspan="2" |[[Cryoglobulinemia]] | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 732: | Line 787: | ||
| | | | ||
|- | |- | ||
! rowspan="4" | ! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Basement Membrane Syndrome | ||
! colspan="2" |[[Anti-glomerular basement membrane antibody|Anti-GBM Disease]] | ! colspan="2" |[[Anti-glomerular basement membrane antibody|Anti-GBM Disease]] | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 753: | Line 810: | ||
|- | |- | ||
! colspan="2" |[[Alport syndrome|Alport's Syndrome]] | ! colspan="2" |[[Alport syndrome|Alport's Syndrome]] | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 772: | Line 831: | ||
|- | |- | ||
! colspan="2" |[[Thin basement membrane disease|Thin Basement Membrane Disease]] | ! colspan="2" |[[Thin basement membrane disease|Thin Basement Membrane Disease]] | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 791: | Line 852: | ||
|- | |- | ||
! colspan="2" |[[Nail-patella syndrome|Nail-Patella Syndrome]] | ! colspan="2" |[[Nail-patella syndrome|Nail-Patella Syndrome]] | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 811: | Line 874: | ||
! rowspan="6" align="center" style="background:#4479BA; color: #FFFFFF;" + | Glomerular-Vascular Syndromes | ! rowspan="6" align="center" style="background:#4479BA; color: #FFFFFF;" + | Glomerular-Vascular Syndromes | ||
! colspan="2" |Atherosclerotic Nephropathy | ! colspan="2" |Atherosclerotic Nephropathy | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 830: | Line 895: | ||
|- | |- | ||
! colspan="2" |[[Hypertensive nephropathy|Hypertensive Nephrosclerosis]] | ! colspan="2" |[[Hypertensive nephropathy|Hypertensive Nephrosclerosis]] | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 849: | Line 916: | ||
|- | |- | ||
! colspan="2" |[[Cholesterol emboli syndrome|Cholesterol Emboli]] | ! colspan="2" |[[Cholesterol emboli syndrome|Cholesterol Emboli]] | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 868: | Line 937: | ||
|- | |- | ||
! colspan="2" |[[Sickle-cell disease|Sickle Cell Disease]] | ! colspan="2" |[[Sickle-cell disease|Sickle Cell Disease]] | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 887: | Line 958: | ||
|- | |- | ||
! colspan="2" |[[Thrombotic microangiopathies|Thrombotic Microangiopathies]] | ! colspan="2" |[[Thrombotic microangiopathies|Thrombotic Microangiopathies]] | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 906: | Line 979: | ||
|- | |- | ||
! colspan="2" |[[Antiphospholipid syndrome|Antiphospholipid Antibody Syndrome]] | ! colspan="2" |[[Antiphospholipid syndrome|Antiphospholipid Antibody Syndrome]] | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 940: | Line 1,015: | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
| | |||
|<nowiki>-</nowiki> | |<nowiki>-</nowiki> | ||
|<nowiki>+</nowiki> | |<nowiki>+</nowiki> | ||
Line 947: | Line 1,023: | ||
* Sub-[[epithelial]] [[immune complex]] deposits | * Sub-[[epithelial]] [[immune complex]] deposits | ||
| + (Granular) | | + (Granular) | ||
| | |||
| | | | ||
|- | |- | ||
! colspan="2" |[[Subacute bacterial endocarditis|Subacute Bacterial Endocarditis]] | ! colspan="2" |[[Subacute bacterial endocarditis|Subacute Bacterial Endocarditis]] | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 969: | Line 1,048: | ||
|- | |- | ||
! colspan="2" |[[Human Immunodeficiency Virus (HIV)|Human Immunodeficiency Virus]] | ! colspan="2" |[[Human Immunodeficiency Virus (HIV)|Human Immunodeficiency Virus]] | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 988: | Line 1,069: | ||
|- | |- | ||
! colspan="2" |[[Hepatitis|Hepatitis B and C]] | ! colspan="2" |[[Hepatitis|Hepatitis B and C]] | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 1,007: | Line 1,090: | ||
|- | |- | ||
! colspan="2" |Other Viruses | ! colspan="2" |Other Viruses | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 1,026: | Line 1,111: | ||
|- | |- | ||
! colspan="2" |[[Syphilis]] | ! colspan="2" |[[Syphilis]] | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 1,045: | Line 1,132: | ||
|- | |- | ||
! colspan="2" |[[Leprosy]] | ! colspan="2" |[[Leprosy]] | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 1,064: | Line 1,153: | ||
|- | |- | ||
! colspan="2" |[[Malaria]] | ! colspan="2" |[[Malaria]] | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 1,083: | Line 1,174: | ||
|- | |- | ||
! colspan="2" |[[Schistosomiasis]] | ! colspan="2" |[[Schistosomiasis]] | ||
| | |||
| | |||
| | | | ||
| | | | ||
Line 1,102: | Line 1,195: | ||
|- | |- | ||
! colspan="2" |Other [[Parasites]] | ! colspan="2" |Other [[Parasites]] | ||
| | |||
| | |||
| | | | ||
| | | |
Revision as of 17:57, 22 May 2018
This page contains general information about Glomerular disease. For more information on specific types, please visit the pages on nephritic syndrome, nephrotic syndrome, Fabry's disease, amyloidosis, pulmonary-renal syndromes (vasculitis), thin basement membrane disease, Alport's Syndrome, anti-GBM Disease, hypertensive nephrosclerosis, and subacute bacterial endocarditis.
Glomerular disease | |
Acute Glomerulonephritis: Micro H&E high mag; an excellent example of acute exudative glomerulonephritis. Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2], Syed Hassan A. Kazmi BSc, MD [3]
Overview
Glomerular disease is a condition that affects the glomerulus. It consists of different diseases with different clinical courses and treatment options. Glomerular disease can be isolated hematuria, isolated proteinuria; acute or chronic glomerulonephritis, and nephrotic or nephritic features of glomerulonephritis. The end stage of all of these diseases will be glomerulosclerosi swhich is characterized by fibrosis of the glomerulus, and end-stage renal disease.
Classification
Glomerular dieseases can be classified into several clinical and pathological syndromes as below:
Syndrome | Disease |
---|---|
Acute nephritic syndromes |
|
Nephrotic syndrome | |
Glomerular Deposition Diseases |
|
Pulmonary-Renal Syndromes: | |
Basement Membrane Syndromes | |
Glomerular-Vascular Syndromes |
|
Infectious Disease–Associated Syndromes |
Also, glomerular diseases can be classified based on their clinical and urinary pattern in to below types:
Mild nephritc:
This category include mild nephritic sediment that is associated with less than half involvement of glomeruli.
Severe nephritic:
More severe clinical features such as edema, heavy proteinuria, hypertension, and/or renal failure may occur.
Nephrotic:
This syndrome is associated with heavy proteinuria and lipiduria.
Glomerular diseases also may classified by their presentation as below:
Glomerular hematuria:
1- Isolated hematuria
2- Glomerulonephritis (nephritic syndrome)
Proteinuria:
1-Isolated non-nephrotic proteinuria
Rapidly progressive glomerulonephritis
Glomerulonephritis
Glomerulonephritis which is inflammation of the glomeruli can be classified based on pathogenic type into three subtypes:
- Immune complex glomerulonephritis: Granular deposit of immune complex.
- Infection mediated types
- Autoimmune types, eg SLE
- MPGN
- IgA nephropathy (Berger nephropathy)
- Membranous nephropathy
- Anti-GBM disease: Linear deposit
- Goodpasture syndrome (renal and lung involvement)
- Renal involvement alone
- Lung involvement alone
- ANCA associated, small vessels vasculitis: Few or no deposit
Glomerulonephritis (nephritic syndrome) also may be classified based on disease course into acute or chronic nephritic syndrome; primary vs secondary causes; or systemic vs renal limited disease. For more information about nephritic syndrome classifications click here.
Pathophysiology
Microscopic Pathology
-
Glomerulonephritis: Micro H&E med mag; an excellent example of AGN with many neutrophils
-
Acute Glomerulonephritis: Micro H&E high mag; an excellent example of acute exudative glomerulonephritis.
Glomerulonephritis Videos
Rapidly progressive glomerulonephritis
{{#ev:youtube|CqSyj4cVZPE}}
Chronic glomerulonephritis
{{#ev:youtube|eA1vYarRAWo}}
Images
-
This is a low-power photomicrograph of a saggital section of end stage chronic glomerulonephritis (GN). Note the marked thinning of the cortex (arrow).
-
This is a higher-power photomicrograph of hyalinized glomeruli (arrows) and glomeruli with thick basement membranes.
-
This is a higher-power photomicrograph of hyalinized glomeruli (1) and glomeruli with thickened basement membranes (2).
-
This is a photomicrograph of interstitial and vascular lesions in end stage renal disease.
-
This is an immunofluorescent photomicrograph of granular membranous immunofluorescence (immune complex disease). The antibody used for these studies was specific for IgG.
-
This is an electron micrograph of subepithelial granular electron dense deposits (arrows) which correspond to the granular immunofluorescence seen in the previous image.
-
This is a photomicrograph of a glomerulus from another case with acute poststreptococcal glomerulonephritis. In this case the immune complex glomerular disease is ongoing with necrosis and accumulation of neutrophils in the glomerulus.
-
This immunofluorescent photomicrograph of a glomerulus from a case of acute poststreptococcal glomerulonephritis shows a granular immunofluorescence pattern consistent with immune complex disease. The primary antibody used for this staining was specific for IgG; however antibodies for complement would show a similar pattern.
-
This electron micrograph demonstrates scattered subepithelial dense deposits (arrows) and a polymorphonuclear leukocyte in the lumen.
-
For comparison this is an immunofluorescent photomicrograph of a glomerulus from a patient with Goodpasture's syndrome. The linear (arrows) immunofluorescence is characteristic of Goodpasture's syndrome.
Images:
Differential Diagnosis
Glomerulonephritis may be proliferative or non-proliferative and may be associated with nephrotic or nephritic features. The various types of glomerulonephritides should be differentiated from each other based on associations, presence of pitting edema, hemeturia, hypertension, hemoptysis, oliguria, peri-orbital edema, hyperlipidemia, type of antibodies, light and electron microscopic features. The following table differentiates between various types of glomerulonephritides:[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24]
Glomerular diseases | Sub-entity | Causes and associations | History and Symtoms | Laboratory Findings | Pathology | Comments | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hyperlipidemia and hypercholesterolemia | Nephrotic features | Nephritic features | Antibodies | ANCA | Anti-glomerular basement membrane antibody (Anti-GBM antibody) | Immune complex formation | Light microscope | Electron microscope | Immunoflourescence pattern | ||||||||||||
History | Pitting edema | Hemeturia (pre-dominantly microscopic) | Hypertension | Hemoptysis | Oliguria | Peri-orbital edema | |||||||||||||||
Acute Nephritic Syndromes | Poststreptococcal Glomerulonephritis | Post infectios: group A beta-hemolytic streptococcus | History of prior skin or throat step infection | +/- | +/- | +/- | +/- | +/- | +/- | +/- | +/- | +/- |
|
|
Pathologic involvement correlates with the clinical findings | ||||||
Subacute Bacterial Endocarditis | Systemic immune reaction to bacterial endocarditis | History of infective endocarditis | +/- | +/- | +/- | +/- | +/- | +/- | +/- | +/- | +/- | ||||||||||
Lupus Nephritis | |||||||||||||||||||||
Antiglomerular Basement Membrane Disease |
|
+/- | + | + | + | + | + | - | - | + | - | + | + |
|
+ (Linear) | ||||||
IgA Nephropathy |
|
+/- | + | + | - | + | +/- | - | - | + | - | - | + |
|
|
- | |||||
ANCA Small-Vessel Vasculitis | Granulomatosis with Polyangiitis (Wegener's) | ||||||||||||||||||||
Microscopic Polyangiitis | |||||||||||||||||||||
Churg-Strauss Syndrome | |||||||||||||||||||||
Membranoproliferative Glomerulonephritis |
|
+/- | + | + | + | + | + | - | + | - | - | - | + |
|
+ (Granular) | ||||||
Mesangioproliferative Glomerulonephritis | |||||||||||||||||||||
Nephrotic Syndrome | Minimal Change Disease |
|
|
+ | - | - | - | +/- | - | + | + | - | - | - | - |
|
|
- | |||
Focal Segmental Glomerulosclerosis |
|
|
+ | - | - | - | +/- | - | + | + | - | - | - | - |
|
|
- | ||||
Membranous Glomerulonephritis |
|
+ | - | - | - | +/- | - | + | + | - | - | - | + |
|
- | ||||||
Diabetic Nephropathy | |||||||||||||||||||||
Glomerular Deposition Diseases | Light Chain Deposition Disease | ||||||||||||||||||||
Renal Amyloidosis | |||||||||||||||||||||
Fibrillary-Immunotactoid Glomerulopathy | |||||||||||||||||||||
Fabry's Disease | |||||||||||||||||||||
Pulmonary-Renal Syndromes: | Goodpasture's syndrome | ||||||||||||||||||||
Microscopic polyangiitis | +/- | + | + | + | + | + | - | - | + |
+ (P-ANCA) |
- | - | - (pauci-immune) | - | |||||||
Churg-Strauss vasculitis | +/- | + | + | + | + | + | - | - | + |
+ (C-ANCA) |
- | - | - (pauci-immune) | - | |||||||
Henoch-Schönlein purpura | |||||||||||||||||||||
Cryoglobulinemia | |||||||||||||||||||||
Basement Membrane Syndrome | Anti-GBM Disease | ||||||||||||||||||||
Alport's Syndrome | |||||||||||||||||||||
Thin Basement Membrane Disease | |||||||||||||||||||||
Nail-Patella Syndrome | |||||||||||||||||||||
Glomerular-Vascular Syndromes | Atherosclerotic Nephropathy | ||||||||||||||||||||
Hypertensive Nephrosclerosis | |||||||||||||||||||||
Cholesterol Emboli | |||||||||||||||||||||
Sickle Cell Disease | |||||||||||||||||||||
Thrombotic Microangiopathies | |||||||||||||||||||||
Antiphospholipid Antibody Syndrome | |||||||||||||||||||||
Infectious Disease–Associated Syndromes | Post-Streptococcal Glomerulonephritis |
|
+/- | + | + | + | + | + | - | - | + | - | - | + |
|
+ (Granular) | |||||
Subacute Bacterial Endocarditis | |||||||||||||||||||||
Human Immunodeficiency Virus | |||||||||||||||||||||
Hepatitis B and C | |||||||||||||||||||||
Other Viruses | |||||||||||||||||||||
Syphilis | |||||||||||||||||||||
Leprosy | |||||||||||||||||||||
Malaria | |||||||||||||||||||||
Schistosomiasis | |||||||||||||||||||||
Other Parasites |
References
- ↑ Saha TC, Singh H (November 2006). "Minimal change disease: a review". South. Med. J. 99 (11): 1264–70. doi:10.1097/01.smj.0000243183.87381.c2. PMID 17195422.
- ↑ Saleem MA, Kobayashi Y (2016). "Cell biology and genetics of minimal change disease". F1000Res. 5. doi:10.12688/f1000research.7300.1. PMC 4821284. PMID 27092244.
- ↑ Keskar V, Jamale TE, Kulkarni MJ, Kiggal Jagadish P, Fernandes G, Hase N (October 2013). "Minimal-change disease in adolescents and adults: epidemiology and therapeutic response". Clin Kidney J. 6 (5): 469–72. doi:10.1093/ckj/sft063. PMC 4438390. PMID 26064510.
- ↑ Chugh SS, Clement LC, Macé C (February 2012). "New insights into human minimal change disease: lessons from animal models". Am. J. Kidney Dis. 59 (2): 284–92. doi:10.1053/j.ajkd.2011.07.024. PMC 3253318. PMID 21974967.
- ↑ Rosenberg AZ, Kopp JB (March 2017). "Focal Segmental Glomerulosclerosis". Clin J Am Soc Nephrol. 12 (3): 502–517. doi:10.2215/CJN.05960616. PMC 5338705. PMID 28242845.
- ↑ Jefferson JA, Shankland SJ (September 2014). "The pathogenesis of focal segmental glomerulosclerosis". Adv Chronic Kidney Dis. 21 (5): 408–16. doi:10.1053/j.ackd.2014.05.009. PMC 4149756. PMID 25168829.
- ↑ Gephardt GN, Tubbs RR, Popowniak KL, McMahon JT (October 1986). "Focal and segmental glomerulosclerosis. Immunohistologic study of 20 renal biopsy specimens". Arch. Pathol. Lab. Med. 110 (10): 902–5. PMID 2429634.
- ↑ Lai WL, Yeh TH, Chen PM, Chan CK, Chiang WC, Chen YM, Wu KD, Tsai TJ (February 2015). "Membranous nephropathy: a review on the pathogenesis, diagnosis, and treatment". J. Formos. Med. Assoc. 114 (2): 102–11. doi:10.1016/j.jfma.2014.11.002. PMID 25558821.
- ↑ Wasserstein AG (April 1997). "Membranous glomerulonephritis". J. Am. Soc. Nephrol. 8 (4): 664–74. PMID 10495797.
- ↑ Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, Wyatt RJ, Scolari F, Mestecky J, Gharavi AG, Julian BA (October 2011). "The pathophysiology of IgA nephropathy". J. Am. Soc. Nephrol. 22 (10): 1795–803. doi:10.1681/ASN.2011050464. PMC 3892742. PMID 21949093.
- ↑ Wyatt RJ, Julian BA (June 2013). "IgA nephropathy". N. Engl. J. Med. 368 (25): 2402–14. doi:10.1056/NEJMra1206793. PMID 23782179.
- ↑ He S, Wu Z (November 2011). "Gene-based Higher Criticism methods for large-scale exonic single-nucleotide polymorphism data". BMC Proc. 5 Suppl 9: S65. doi:10.1186/1753-6561-5-S9-S65. PMC 3287904. PMID 22373436.
- ↑ Higgins RM, Goldsmith DJ, Connolly J, Scoble JE, Hendry BM, Ackrill P, Venning MC (January 1996). "Vasculitis and rapidly progressive glomerulonephritis in the elderly". Postgrad Med J. 72 (843): 41–4. PMC 2398323. PMID 8746284.
- ↑ Jennette JC (March 2003). "Rapidly progressive crescentic glomerulonephritis". Kidney Int. 63 (3): 1164–77. doi:10.1046/j.1523-1755.2003.00843.x. PMID 12631105.
- ↑ Bolton WK (November 1996). "Goodpasture's syndrome". Kidney Int. 50 (5): 1753–66. PMID 8914046.
- ↑ Mathew TH, Hobbs JB, Kalowski S, Sutherland PW, Kincaid-Smith P (February 1975). "Goodpasture's syndrome: normal renal diagnostic findings". Ann. Intern. Med. 82 (2): 215–8. PMID 1090223.
- ↑ Renaudineau Y, Le Meur Y (October 2008). "Renal involvement in Wegener's granulomatosis". Clin Rev Allergy Immunol. 35 (1–2): 22–9. doi:10.1007/s12016-007-8066-6. PMID 18172777.
- ↑ Weiss MA, Crissman JD (October 1984). "Renal biopsy findings in Wegener's granulomatosis: segmental necrotizing glomerulonephritis with glomerular thrombosis". Hum. Pathol. 15 (10): 943–56. PMID 6384024.
- ↑ Sinico RA, Di Toma L, Maggiore U, Tosoni C, Bottero P, Sabadini E, Giammarresi G, Tumiati B, Gregorini G, Pesci A, Monti S, Balestrieri G, Garini G, Vecchio F, Buzio C (May 2006). "Renal involvement in Churg-Strauss syndrome". Am. J. Kidney Dis. 47 (5): 770–9. doi:10.1053/j.ajkd.2006.01.026. PMID 16632015.
- ↑ Cartin-Ceba R, Keogh KA, Specks U, Sethi S, Fervenza FC (September 2011). "Rituximab for the treatment of Churg-Strauss syndrome with renal involvement". Nephrol. Dial. Transplant. 26 (9): 2865–71. doi:10.1093/ndt/gfq852. PMC 3218640. PMID 21325353.
- ↑ Chung SA, Seo P (August 2010). "Microscopic polyangiitis". Rheum. Dis. Clin. North Am. 36 (3): 545–58. doi:10.1016/j.rdc.2010.04.003. PMC 2917831. PMID 20688249.
- ↑ Pagnoux C (March 2008). "[Wegener's granulomatosis and microscopic polyangiitis]". Rev Prat (in French). 58 (5): 522–32. PMID 18524109.
- ↑ Alchi B, Jayne D (August 2010). "Membranoproliferative glomerulonephritis". Pediatr. Nephrol. 25 (8): 1409–18. doi:10.1007/s00467-009-1322-7. PMC 2887509. PMID 19908070.
- ↑ Davis AE, Schneeberger EE, Grupe WE, McCluskey RT (May 1978). "Membranoproliferative glomerulonephritis (MPGN type I) and dense deposit disease (DDD) in children". Clin. Nephrol. 9 (5): 184–93. PMID 657595.